X4 Pharmaceuticals Inc

NASDAQ:XFOR  
1.25
+0.07 (+5.93%)
Earnings Announcements

X4 Pharmaceuticals Reports Q4, Full Year 2021 Financial Results

Published: 03/17/2022 10:11 GMT
X4 Pharmaceuticals Inc (XFOR) - X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update.
X4 Had $83.1 Million in Cash, Cash Equivalents, and Restricted Cash As of December 31, 2021.
Expects That Its Cash and Cash Equivalents Will Fund Company Operations Into Q4 of 2022.
Expects That Its Cash and Cash Equivalents Will Fund Company Operations Into Q4 of 2022.
Qtrly Loss per Share $1.24.
Q4 Earnings per Share View $-0.68 -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.63

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.56

More details on our Analysts Page.